Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1594 • ACR Convergence 2022
Incidence of Pneumocystis Jirovecii Pneumonia and Prophylaxis-Associated Adverse Events Among Patients with Systemic Lupus Erythematosus
Yiran Jiang¹, Ali Duarte-Garcia², Mike Putman³ and David Gazeley⁴, ¹Medical College of Wisconsin, Milwaukee, WI, ²Mayo Clinic, Rochester, MN, ³The Medical College of Wisconsin, Milwaukee, WI, ⁴Medical College of Wisconsin, Wauwatosa, WI
Background/Purpose: Pneumocystis jirovecii Pneumonia (PJP) is an opportunistic infection that may affect patients receiving immunosuppression. There are no consensus guidelines for PJP prophylaxis among patients…
Abstract Number: 1708 • ACR Convergence 2022
A Role for the RAGE Receptor in Chronic Neurotoxicity After Exposure to SLE Antibodies That Cross React with dsDNA and the NMDA Receptor
Bahtiyar Toz¹, Jeffrey C wingard², Bruce Volpe² and Betty Diamond², ¹Resident in Queens Hospital Center, Jamaica, NY, ²Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Neurologic dysfunction occurs in up to 80% of SLE patients. Cognitive impairment is one of the most frequent manifestations of neuropsychiatric SLE (NPSLE). There…
Abstract Number: 1764 • ACR Convergence 2022
Utilization of Electronic Health Record Data to Evaluate the Impact of Urban Environment on Risk of Systemic Lupus Erythematosus Symptoms
Janet Song¹, Noah Forrest¹, Kathleen Mittendorf², Wei-Qi Wei², Leah Kottyan³, Rosalind Ramsey-Goldman¹, Theresa Walunas¹ and Abel Kho¹, ¹Feinberg School of Medicine, Chicago, IL, ²Vanderbilt University Medical Center, Nashville, TN, ³Cincinnati Children's Hospital Medical Center, Cincinatti, OH
Background/Purpose: Systemic Lupus Erythematosus (SLE) has a complex and poorly understood etiology and is difficult to diagnose due to its varied presentation across many organ…
Abstract Number: 2060 • ACR Convergence 2022
Increased Risk of Adverse Renal Outcomes in Patients of African Ancestry with Systemic Lupus Erythematosus (SLE) – Role of APOL1
Gul Karakoc, Ge Liu, Jorge Gamboa, Cecilia Chung, Jonathan Mosley, Michael Stein and Vivian Kawai, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: SLE disproportionately affects individuals of African (AA) compared to European ancestry (EA). In addition to a higher incidence, the disease is more severe in…
Abstract Number: 2078 • ACR Convergence 2022
Mesangial Lupus Nephritis: Long Term Outcomes
KONSTANTINOS TSELIOS¹, Dafna Gladman², Jiandong Su³ and Murray Urowitz⁴, ¹McMaster University, Population Health Research Institute, Hamilton, ON, Canada, ²Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada
Background/Purpose: Mesangial lupus nephritis (LN class II) is generally considered benign with minimal potential for developing advanced chronic kidney disease (CKD). However, a certain proportion…
Abstract Number: 2098 • ACR Convergence 2022
Analysis of Cutaneous Lupus Hospitalizations: A United States National Population-based Study
Ehizogie Edigin¹, Amy Trang², Chinenye Osuorji³, Christopher Hino¹, Solomon Anighoro⁴, Precious Eseaton⁵, Nneka Chukwu⁶, Osaigbokan Aihie⁷, Augustine Manadan² and vaneet Sandhu⁸, ¹Loma Linda University Health, Loma Linda, CA, ²Rush University Medical Center, Chicago, IL, ³Montefiore Medical Center/ Albert Einstein College of Medicine, Bronx, NY, ⁴St. Helens and Knowsley Teaching hospitals NHS Trust, Prescot, England, United Kingdom, ⁵University of South Wales, Cardiff, Wales, United Kingdom, ⁶Nuvance Health, Poughkeepsie, ⁷University of Missouri, St. Loius, MO, ⁸Loma Linda University, Loma Linda, CA
Background/Purpose: Lupus can present as either systemic lupus erythematous (SLE) and/or a cutaneous form known as cutaneous lupus erythematous (CLE). While a lot of data…
Abstract Number: 2222 • ACR Convergence 2022
Lupus Clinical Flares in Patients with Gut Pathobiont Blooms Share a Novel Peripheral Blood Transcriptomic Immune Activation Profile
Gregg Silverman¹, Macintosh Cornwell¹, Peter Izmirly¹, Mala Masson¹, Jill Buyon¹, Doua Azzouz² and Kelly Ruggles¹, ¹NYU Grossman School of Medicine, New York, NY, ²NYU Gross School of Medicine, New York, NY
Background/Purpose: SLE is an inflammatory condition associated with hyperactivation of the immune system, with mounting evidence that imbalances in the gut microbiota communities are common.…
Abstract Number: 0056 • ACR Convergence 2022
Pilot Study to Implement the Type 1 & 2 SLE Model in an Academic Rheumatology Clinic
Amanda Eudy¹, Jennifer Rogers², Kai Sun³, Rebecca Sadun³, David Pisetsky⁴, Mithu Maheswaranathan², Jayanth Doss³, Lisa Criscione-Schreiber⁵ and Megan Clowse³, ¹Duke University, Raleigh, NC, ²Duke, Durham, NC, ³Duke University, Durham, NC, ⁴Duke University Medical Center, Durham, NC, ⁵Duke University School of Medicine, Durham, NC
Background/Purpose: The Type 1 & 2 SLE Model was developed to better explain the signs, symptoms, and management goals of SLE to patients. We assembled…
Abstract Number: 0110 • ACR Convergence 2022
Does Access Reduce Excess Use? Lupus Outcomes in Two Distinct Socioeconomic Groups Seen by University Rheumatologists
Alissa Chandler¹, Rodney Tehrani¹ and Varun Bhalla², ¹Loyola University Medical Center, Maywood, IL, ²Loyola University Medical cneter, Chicago, IL
Background/Purpose: SLE is a multi-organ chronic autoimmune disease, which requires chronic medication use and close follow up with a rheumatologist. Poor disease control can lead…
Abstract Number: 0326 • ACR Convergence 2022
Mapping Anti-Mitochondrial Antibodies over Time in a Lupus Inception Cohort
Yann Becker¹, Éric Boilard¹, Emmanuelle Rollet-Labelle¹, Christian Lood², Anne-Sophie Julien³, Joannie Leclerc¹, Tania Lévesque¹, Murray Urowitz⁴, John Hanly⁵, Caroline Gordon⁶, Sang-Cheol Bae⁷, Juanita Romero-Diaz⁸, Jorge Sanchez-Guerrero⁹, Ann E Clarke¹⁰, Sasha Bernatsky¹¹, Daniel Wallace¹², David Isenberg¹³, Anisur Rahman¹⁴, Joan Merrill¹⁵, Dafna Gladman¹⁶, Ian N. Bruce¹⁷, Michelle Petri¹⁸, Ellen M. Ginzler¹⁹, Mary Anne Dooley²⁰, Rosalind Ramsey-Goldman²¹, Susan Manzi²², Andreas Jönsen²³, Graciela Alarcón²⁴, Ronald van Vollenhoven²⁵, Cynthia Aranow²⁶, Guillermo Ruiz-Irastorza²⁷, S. Sam Lim²⁸, Murat Inanc²⁹, Kenneth Kalunian³⁰, Soren Jacobsen³¹, Christine Peschken³², Diane Kamen³³, Anca Askanase³⁴, Jill Buyon³⁵ and Paul R Fortin³⁶, ¹Centre de Recherche ARThrite, CHU de Québec - Université Laval, Québec, QC, Canada, ²Division of Rheumatology, University of Washington, Seattle, WA, ³Université Laval, Québec, QC, Canada, ⁴University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada, ⁵Division of Rheumatology, Queen Elizabeth II Health Sciences Center (Nova Scotia Rehabilitation Site) and Dalhousie University, Halifax, NS, Canada, ⁶Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ⁷Hanyang University Medical Center, Seoul, Republic of Korea, ⁸Instituto Nacional de Ciencias Medicas y Nutricion SZ, Ciudad de México, Mexico, ⁹Mount Sinai Hospital and University Health Network, University of Toronto, Toronto, ON, Canada, ¹⁰University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, ¹¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ¹²Cedars-Sinai Medical Center, Los Angeles, CA, ¹³University College London, London, United Kingdom, ¹⁴Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ¹⁷Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, ¹⁸Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ¹⁹SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, ²⁰Raleigh Neurology Associates, Chapel Hill, NC, ²¹Northwestern University Feinberg School of Medicine, Chicago, USA, Chicago, IL, ²²Allegheny Health Network, Lupus Center of Excellence, Wexford, PA, ²³Department of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Lund and Skåne University Hospital, Lund, Sweden, ²⁴The University of Alabama at Birmingham, Oakland, ²⁵Amsterdam University Medical Centers, Amsterdam, Netherlands, ²⁶Feinstein Institutes for Medical Research, Manhasset, NY, ²⁷Autoimmune Diseases Research Unit, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, UPV/EHU, Barakaldo, Spain, ²⁸Emory University, Atlanta, GA, ²⁹Division of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istambul, Turkey, ³⁰University of California San Diego, La Jolla, CA, ³¹Rigshospitalet, Copenhagen, Denmark, ³²University of Manitoba, Winnipeg, MB, Canada, ³³Medical University of South Carolina, Charleston, SC, ³⁴Columbia University Medical Center, New York, NY, ³⁵NYU Grossman School of Medicine, New York, NY, ³⁶Centre ARThrite - CHU de Québec - Université Laval, Québec, QC, Canada
Background/Purpose: Mitochondria can be both pro-inflammatory and antigenic. We hypothesize (1) that anti-mitochondrial antibodies (AMA) are present in lupus and (2) can predict outcomes. Our…
Abstract Number: 0344 • ACR Convergence 2022
Therapeutic Thresholds of Hydroxychloroquine Blood Levels: Physiologic and Social Determinants of Low Hydroxychloroquine Blood Levels
Shivani Garg¹, Betty Chewning², Brad Astor³ and Christie Bartels⁴, ¹University of Madison, School of Medicine and Public Health, Madison, WI, ²University of Wisconsin, School of Pharmacy, Madison, WI, ³University of Wisconsin, School of Medicine and Public Health, Madison, WI, ⁴University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Lupus, the leading cause of chronic kidney disease (CKD) in young women, is treated with Hydroxychloroquine (HCQ) which is primarily excreted by kidneys. Yet…
Abstract Number: 0366 • ACR Convergence 2022
Phase II Trial of Enpatoran in Patients Hospitalized with COVID-19 Pneumonia
John McKinnon¹, Joel Santiaguel², Claudia Murta De Oliveira³, Dongzi Yu⁴, Mukhy Khursheed⁵, Flavie Moreau⁶, Lena Klopp-Schulze⁷, Jamie Shaw⁸, Sanjeev Roy⁹ and Amy Kao¹⁰, ¹Department of Medicine, Henry Ford Hospital, Detroit, MI, ²Internal Medicine, Quirino Memorial Medical Center, Quezon City, Philippines, ³Ambulatório de Pesquisa Clínica, Santa Casa de Misericórdia, Belo Horizonte, Brazil, ⁴Global Clinical Development, EMD Serono, Billerica, MA, ⁵Global Patient Safety, Merck Serono Ltd., an affiliate of Merck KGaA, Darmstadt, Germany, ⁶Global Biostatistics, EMD Serono, Billerica, MA, ⁷Translational Medicine, the healthcare business of Merck KGaA, Darmstadt, Germany, ⁸Translational Medicine, EMD Serono, Billerica, MA, ⁹Global Clinical Development, Ares Trading SA, an affiliate of Merck KGaA, Darmstadt, Germany, ¹⁰EMD Serono, Billerica, MA
Background/Purpose: Enpatoran is a selective and potent dual toll-like receptor (TLR) 7/8 inhibitor in development for the treatment of cutaneous and systemic lupus erythematosus (CLE/SLE).…
Abstract Number: 0631 • ACR Convergence 2022
Perfluoroalkyl Substances and Community Vulnerability: Associations with Lupus-Related Autoantibodies and Disease
Emily Vara, Dulaney Wilson, John Pearce, Jim Oates and Diane Kamen, Medical University of South Carolina, Charleston, SC
Background/Purpose: Perfluoroalkyl substances (PFAS) are a class of persistent organic pollutants found in nonstick products, water repellant fabrics, fire-retardant foams, and food packaging. Highly stable,…
Abstract Number: 0649 • ACR Convergence 2022
Phosphofructokinase P Fine-Tunes T Regulatory Cell Metabolism, Function and Stability in Systemic Autoimmunity
Marc Scherlinger¹, Wenliang Pan², Ryo Hisada¹, Milena Vukelic³, Masataka Umeda¹, Afroditi Boulougoura², Maria Tsokos¹ and George Tsokos², ¹BIDMC Harvard University, Boston, MA, ²Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³Albert Einstein College of Medicine, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by a defective T regulatory (Treg) cell compartment which participate in immune dysregulation. Although the underlying mechanism are…
Abstract Number: 0669 • ACR Convergence 2022
Understanding How Type I Interferon Modulates Langerhans Cell ADAM17 to Promote Photosensitivity in Lupus
Thomas Li¹, Ethan Seltzer¹, Victoria Zyulina¹, Keila Veiga², Noa Schwartz³, Yurii Chinenov¹, David Oliver¹, Jose Lora⁴, Ali Jabbari⁵, Yong Liu¹, Hafsa Munir¹, William Shipman¹, Marvin Sandoval¹, Isabel Sollohub¹, william ambler¹, Bikash Mishra⁴, sarah taber¹, karen onel¹, Mehdi Rashighi⁶, james krueger⁷, Niroshana Anandasabapathy⁴, Carl Blobel¹ and theresa Lu¹, ¹Hospital for Special Surgery, New York, NY, ²Maria Fareri Children's Hospital, New York, NY, ³Albert Einstein College of Medicine, New York, NY, ⁴Weill Cornell Medicine, New York, NY, ⁵University of Iowa, Iowa City, IA, ⁶University of Massachusetts Medical School, Worcester, MA, ⁷Rockefeller University, New York, NY
Background/Purpose: Photosensitivity is a hallmark symptom of lupus erythematosus (LE), in which patients develop inflammatory skin lesions in response to ultraviolet radiation (UVR). In examining…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].